Search results
Results from the WOW.Com Content Network
The forced expression of oncogenic Ras in cultured human MCF-10A breast cancer cells markedly up-regulates BLT2 receptors and this up-regulation appears essential for the epithelial–mesenchymal transition-promoting ability of transforming growth factor beta in these cells; BLT2 receptors in these cells appear to stimulate the production of ...
[5] [6] miR-205 expression is associated with survival in breast cancer. Patients with higher expression have higher probability of survival. [7] This down regulation was also observed in breast cancer cell lines, including MCF-7 and MDA-MB-231 compared to the non-malignant cell line MCF-10A.
Osimertinib, sold under the brand name Tagrisso, [6] is a medication used to treat non-small-cell lung carcinomas with specific mutations. [7] [8] It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
Elacestrant was not McDonnell’s first attempt at bringing a breast cancer drug to market. In 1996, his lab developed a similar drug, etacstil, which was the first oral medication in this class ...
For premium support please call: 800-290-4726 more ways to reach us
AOH1996 is an experimental anticancer medication which acts as a small molecule inhibitor of proliferating cell nuclear antigen (PCNA) and is in Phase I clinical trials at City of Hope as of August 2023 for the treatment of solid tumors.
Each drug is listed once (at present), though it might fall in more than one subsection. A full alphabetical listing is included after the categorical listing. The agents in this list are often combined into chemotherapy agent for polychemotherapy (combination chemotherapy).
Originally the cell line was named MCF-7/ADR-RES; it was renamed together with the change in classification. [8] Two brain cancer cell lines, SNB-19 and U251, were discovered to come from the same person. [9] This makes a mixup likely. A 61st cell line, MDA-N, has been confirmed to being derived from the misclassified MDA-MB-435 cell line. [7]